This further elucidates that TRIP6 might influence the glycolytic capacity of CRC cells through its effect on GPI expression, though further longitudinal studies are required to validate these findings and to ascertain their direct impact on patient prognosis and survival rates. This evidence concerns the gene TRIP6 and colorectal carcinoma.